Advancing Regulatory Oversight of Medical Device Trials to Align with Clinical Drug Standards in the European Union
Pharmaceuticals · 12.06.2025 · 18 (6) · 876
DOI: 10.3390/ph18060876 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 12.06.2025. Verfasst von Ádám Pannonhalmi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology, University of Szeged, Korányi Alley 6, H-6720 Szeged, Hungary. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Szeged Open Access Fund.
Abstract (Originalsprache)
The regulation of clinical trials for medicinal products and medical devices has undergone numerous changes in recent years in the European Union, challenging manufacturers and national regulatory agencies as well. With the introduction of combined drug–device products, the regulatory landscape has been drastically changed to adapt to novel technological advancements and innovations. A comparative analysis has not yet been published highlighting the main differences and common elements of these two medicinal products, which took up almost all of the market in the pharmaceutical sector. Due to stricter regulations in the field of medical devices, the process from application up until post-market surveillance became more difficult, but a correlation between the regulation of drug trials can also be found. The main differences lie in the risk management systems, where, regardless of the background knowledge of a drug, it is always strict and mandatory structured progress, while in the case of medical devices, it is more flexible based on the risk category of the product. Generally, the utilization of e-health opportunities, transparency, and data accessibility have been improved in both fields. Via the adaptation of the mentioned regulation in the EU, the safety of patients and the efficacy of trials have been greatly increased. This manuscript aims to compare the specific regulations of these two types of medicinal products with a brief outlook on the non-EU sector as well.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology and Allergology, University of Szeged, Korányi Alley 6, H-6720 Szeged, Hungary.
- Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös Street 6, H-6720 Szeged, Hungary.
- Competence Centre of Pharmaceutical Development and Clinical Trials, Centre of Excellence for Interdisciplinary Research, Development and Innovation, University of Szeged, Dugonics Square 13, H-6720 Szeged, Hungary.
ORCID-Profile: Bence Sipos, Gábor Katona, Lajos Kemény, Ildikó Csóka
Förderung
- University of Szeged Open Access Fund
Zitieren
APA
Pannonhalmi, Á., Sipos, B., Kurucz, R. I., Katona, G., Kemény, L., & Csóka, I. (2025). Advancing Regulatory Oversight of Medical Device Trials to Align with Clinical Drug Standards in the European Union. Pharmaceuticals, 18(6), 876. https://doi.org/10.3390/ph18060876
Vancouver
Pannonhalmi Á, Sipos B, Kurucz RI, Katona G, Kemény L, Csóka I. Advancing Regulatory Oversight of Medical Device Trials to Align with Clinical Drug Standards in the European Union. Pharmaceuticals. 2025;18(6):876. doi:10.3390/ph18060876
BibTeX
@article{Pannonhalmi2025,
author = {Pannonhalmi, Ádám and Sipos, Bence and Kurucz, Róbert Imre and Katona, Gábor and Kemény, Lajos and Csóka, Ildikó},
title = {Advancing Regulatory Oversight of Medical Device Trials to Align with Clinical Drug Standards in the European Union},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {6},
pages = {876},
doi = {10.3390/ph18060876}
}
EUVIMED